questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines inhibitrices de la fraction C1 du complément
C1 Inhibiteur
C1 Inhibiteur : Questions médicales fréquentes
Termes MeSH sélectionnés :
Randomized Controlled Trials as Topic
Diagnostic
5
Déficience en C1 inhibiteur
Tests de laboratoire
Protéines du complément
Tests de laboratoire
Antécédents médicaux
Hérédité
Symptômes
5
Maladies auto-immunes
Allergies
Prévention
5
Allergies alimentaires
Réactions
Stress
Facteurs déclenchants
Traitements
5
Traitement
Médicaments anti-inflammatoires
Corticostéroïdes
Inflammation
Thérapie génique
Traitements expérimentaux
Crise aiguë
Administration de médicaments
Complications
5
Œdème laryngé
Difficultés respiratoires
Maladies auto-immunes
Risque accru
Qualité de vie
Symptômes chroniques
Surveillance médicale
Complications
Facteurs de risque
5
Facteurs de risque
Hérédité
Facteurs environnementaux
Crises
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "C1 Inhibiteur : Questions médicales les plus fréquentes",
"headline": "C1 Inhibiteur : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les C1 Inhibiteur : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-06",
"dateModified": "2025-05-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "C1 Inhibiteur"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines inhibitrices de la fraction C1 du complément",
"url": "https://questionsmedicales.fr/mesh/D003174",
"about": {
"@type": "MedicalCondition",
"name": "Protéines inhibitrices de la fraction C1 du complément",
"code": {
"@type": "MedicalCode",
"code": "D003174",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.872.140"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "C1 Inhibiteur",
"alternateName": "Complement C1 Inhibitor Protein",
"code": {
"@type": "MedicalCode",
"code": "D050718",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Henriette Farkas",
"url": "https://questionsmedicales.fr/author/Henriette%20Farkas",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary. farkas.henriette@med.semmelweis-univ.hu."
}
},
{
"@type": "Person",
"name": "Lilian Varga",
"url": "https://questionsmedicales.fr/author/Lilian%20Varga",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary."
}
},
{
"@type": "Person",
"name": "Anastasios E Germenis",
"url": "https://questionsmedicales.fr/author/Anastasios%20E%20Germenis",
"affiliation": {
"@type": "Organization",
"name": "Department of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece."
}
},
{
"@type": "Person",
"name": "Andrea Zanichelli",
"url": "https://questionsmedicales.fr/author/Andrea%20Zanichelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Via G.B. Grassi 74, 20157 Milan, Italy."
}
},
{
"@type": "Person",
"name": "Chiara Suffritti",
"url": "https://questionsmedicales.fr/author/Chiara%20Suffritti",
"affiliation": {
"@type": "Organization",
"name": "ASST-Fatebenefratelli-Sacco, Milan, Italy. chiarasuffritti@gmail.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37162564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-023-06083-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08334-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design and Methodological Issues of Within-Person (Split-Body) Randomized Controlled Trials Evaluating a Topical Treatment: A Systematic Review.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36990057",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530149"
}
},
{
"@type": "ScholarlyArticle",
"name": "Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36800063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03734-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37145134",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-023-07055-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines inhibitrices de la fraction C1 du complément",
"item": "https://questionsmedicales.fr/mesh/D003174"
},
{
"@type": "ListItem",
"position": 5,
"name": "C1 Inhibiteur",
"item": "https://questionsmedicales.fr/mesh/D050718"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : C1 Inhibiteur - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur C1 Inhibiteur",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur C1 Inhibiteur",
"description": "Comment diagnostiquer une déficience en C1 inhibiteur ?\nQuels tests sont utilisés pour évaluer le C1 inhibiteur ?\nQuels symptômes indiquent un problème de C1 inhibiteur ?\nLe diagnostic nécessite-t-il une consultation spécialisée ?\nPeut-on diagnostiquer par des antécédents familiaux ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur C1 Inhibiteur",
"description": "Quels sont les symptômes d'une carence en C1 inhibiteur ?\nLes symptômes varient-ils selon l'âge ?\nLes œdèmes sont-ils toujours présents ?\nY a-t-il des symptômes associés à des infections ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur C1 Inhibiteur",
"description": "Comment prévenir les crises d'œdème ?\nLes patients doivent-ils éviter certains aliments ?\nLe stress influence-t-il les crises ?\nDes vaccinations sont-elles recommandées ?\nLes patients doivent-ils porter un bracelet médical ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur C1 Inhibiteur",
"description": "Quels traitements sont disponibles pour la carence en C1 inhibiteur ?\nLe traitement préventif est-il nécessaire ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nComment gérer une crise aiguë ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur C1 Inhibiteur",
"description": "Quelles sont les complications possibles de la carence en C1 inhibiteur ?\nLes œdèmes peuvent-ils entraîner des complications graves ?\nY a-t-il un risque accru de maladies auto-immunes ?\nLes complications peuvent-elles affecter la qualité de vie ?\nLes complications nécessitent-elles une surveillance régulière ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur C1 Inhibiteur",
"description": "Quels sont les facteurs de risque de carence en C1 inhibiteur ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe influence-t-il le risque de carence ?\nL'âge joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050718?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en C1 inhibiteur ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage sanguin du C1 inhibiteur et des tests fonctionnels sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le C1 inhibiteur ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le dosage du C1 inhibiteur et l'évaluation de l'activité fonctionnelle."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de C1 inhibiteur ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des œdèmes, des douleurs abdominales et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une consultation spécialisée ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une consultation en immunologie ou en allergologie est souvent recommandée."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par des antécédents familiaux ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de symptômes similaires peuvent orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en C1 inhibiteur ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des œdèmes récurrents, des douleurs abdominales et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître à tout âge, mais souvent durant l'enfance ou l'adolescence."
}
},
{
"@type": "Question",
"name": "Les œdèmes sont-ils toujours présents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les œdèmes peuvent être intermittents et ne pas se manifester constamment."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections peuvent exacerber les symptômes liés à la carence en C1 inhibiteur."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être similaires à ceux d'autres troubles allergiques ou auto-immuns."
}
},
{
"@type": "Question",
"name": "Comment prévenir les crises d'œdème ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les déclencheurs connus et suivre un traitement préventif régulier."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains aliments peuvent déclencher des réactions, il est conseillé de les identifier."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les crises ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut être un facteur déclenchant pour certaines personnes."
}
},
{
"@type": "Question",
"name": "Des vaccinations sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections qui aggravent les symptômes."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils porter un bracelet médical ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bracelet médical peut alerter en cas d'urgence liée à la carence en C1 inhibiteur."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la carence en C1 inhibiteur ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des concentrés de C1 inhibiteur et des médicaments anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Le traitement préventif est-il nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement préventif peut être recommandé pour éviter les crises d'œdème."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les corticostéroïdes peuvent réduire l'inflammation, mais ne traitent pas la cause sous-jacente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies géniques et des traitements ciblés sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer une crise aiguë ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'administration rapide de C1 inhibiteur est essentielle lors d'une crise aiguë."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la carence en C1 inhibiteur ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des œdèmes sévères, des infections et des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Les œdèmes peuvent-ils entraîner des complications graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des œdèmes laryngés peuvent provoquer des difficultés respiratoires potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies auto-immunes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de développer des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes chroniques et les crises peuvent significativement altérer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles une surveillance régulière ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière est essentielle pour gérer les complications potentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de carence en C1 inhibiteur ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections récurrentes peuvent exacerber les symptômes chez les patients."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de carence ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la carence en C1 inhibiteur est plus fréquente chez les femmes que chez les hommes."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge, bien que les symptômes apparaissent souvent plus tôt."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent déclencher des crises chez les individus sensibles."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 01/05/2025
Contenu vérifié selon les dernières recommandations médicales
8 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary. farkas.henriette@med.semmelweis-univ.hu.
4 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary.
Publications dans "C1 Inhibiteur" :
4 publications dans cette catégorie
Affiliations :
Department of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
CeMIA SA, Larissa, Greece.
Publications dans "C1 Inhibiteur" :
4 publications dans cette catégorie
Affiliations :
Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Via G.B. Grassi 74, 20157 Milan, Italy.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
ASST-Fatebenefratelli-Sacco, Milan, Italy. chiarasuffritti@gmail.com.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
CeMIA SA, Larissa, Greece.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Allergology, Navy Hospital, Athens, Greece.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
Publications dans "C1 Inhibiteur" :
3 publications dans cette catégorie
Affiliations :
Department of Translational Medicine, University of Naples, Via S. Pansini 5, 80131 Naples, Italy.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Translational Medicine, Division of Medical Protein Chemistry, Lund University, Malmö, Sweden.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Centre, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands.
Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Szentkiralyi u. 46, Budapest, 1088, Hungary.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Publications dans "C1 Inhibiteur" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Eastern Virginia Medical School, 700 West Olney Road, Norfolk, VA 23507, USA.
Children's Specialty Group, 811 Redgate Avenue, Norfolk, VA 23507, USA.
Children's Hospital of the King's Daughters, 601 Children's Lane, Norfolk, VA 23507, USA.
Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, 700 West Olney Road, Norfolk, VA 23507-1696, USA.
Publications dans "C1 Inhibiteur" :
Diquafosol enhances fluid transfer and mucin secretion on ocular surface, which has been suggested as an effective treatment for dry eye disease (DED). The aim of the systematic review and meta-analys...
Relevant randomized controlled trials were obtained via search of electronic including PubMed, Embase, Cochrane Library, and Web of Science. A random-effects model was used to pool the results after i...
A total of nine RCTs involving 1295 patients with DED were included in the meta-analysis. Compared to treatment with 0.1% HA, topical treatment with 3% diquafosol significantly improved the Ocular Sur...
Topical treatment with 3% diquafosol may be more effective than 0.1% HA for patients with DED. However, the long-term efficacy and tolerability of diquafosol still need to be determined....
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Topical drugs are often used as first-line treatment for dermatological conditions. A within-person design may then be well adapted: it consists of randomizing lesions/body sites rather than patients,...
The aim of this review was to provide a methodological overview of within-person randomized trials (WP-RCTs) in dermatology....
We searched for eligible trials published between 2017 and 2021 in MEDLINE, Embase, and Central in dermatology journals and the 6 highest-impact-factor general medical journals. Two authors selected p...
From 1,034 articles identified, we included 54 WP-RCTs, mainly for acne vulgaris, psoriasis, actinic keratosis, and atopic dermatitis. In most of the trials, patients had only 2 lesions/body sites. In...
Our systematic review highlights that despite the publication of the CONSORT checklist extension for WP-RCTs in 2017, this design is rarely used, and when it is, there are methodological and reporting...
We aim to evaluate the clinical efficacy and safety of using laser and light combined with topical minoxidil for alopecia areata. We searched PubMed, Embase, Web of Science, the Cochrane Library, Chin...
Vulvar lichen sclerosus (LS) is a chronic debilitating inflammatory skin disease. Today, the gold standard is a life-long topical steroid treatment. Alternative options are highly desired. We present ...
We recruited 66 patients, 44 in the laser arm and 22 in the steroid arm. Patients with a physician-administered clinical LS score ≥ 4 were included. Participants received either four laser treatments ...
The findings of this trial have the potential to offer a novel treatment option for LS. The standardized Nd:YAG/Er:YAG laser settings and the treatment regime are presented in this paper....
NCT03926299....
Alopecia areata (AA) is a common autoimmune skin disease. Our study aimed to systematically evaluate the efficacy and safety of compound glycyrrhizin (CG) combined with topical minoxidil therapy in tr...
We searched the PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases. Randomized controlled trials (RCTs) on CG combined with topical minoxidil therapy compared with topi...
11 RCTs and 1189 patients were included. Compared with topical minoxidil therapy alone, CG combined with topical minoxidil therapy was more effective at improving the clinical efficacy (RR = 1.36, 95%...
The current evidence indicates that CG combined with topical minoxidil therapy is effective and safe for AA. However, owing to the suboptimal quality of the included studies, more high-quality and lar...
The purpose was to identify and summarize the existing evidence on the efficacy and safety of the topical application of olive oil for preventing pressure ulcers (PUs). We included only randomized con...
To investigate the clinical efficacy and safety of topical difamilast in mild-to-moderate atopic dermatitis (AD)....
Only randomized controlled trials (RCTs) that compared topical difamilast with vehicle treatment for patients with AD were included. PubMed, Web of Science, Ovid Medline, Cochrane Library, ClinicalTri...
Five studies enrolling a total of 1009 patients with mild-to-moderate AD were identified. Compared with the topical vehicle, topical difamilast was associated with a significantly higher success rate ...
This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD....
Melasma is a chronic relapsing skin condition. Laser therapy is a new advancement in treatment. Whether the topical application of tranexamic acid (TXA) increases the efficacy of laser therapy in mela...
Randomized controlled trials are used to estimate the causal effect of a treatment on a health outcome of interest in a patient population. Often the specified treatment in a randomized controlled tri...
We use causal reasoning to explain why randomized controlled trials of biomarker targets can arrive at conflicting or misleading conclusions. We describe four key threats to the validity of trials of ...
We illustrate these findings using evidence from 15 randomized controlled trials of blood pressure targets for management of hypertension. Randomized trials of blood pressure targets exhibit substanti...
Researchers should critically assess meta-analyses of trials of targets for variation in the types, distributions, and off-target effects of therapies studied. Trial investigators should release detai...